It is used both to treat tumours and to help clinicians determine whether they are cancerous, as well as their grade and ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Neoadjuvant sacituzumab govitecan plus pembrolizumab achieved a 39% clinical complete response requiring concordant radiographic negativity and pathologic clearance ...